Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising results," Robert M. Jotte, M.D., Ph.D., principal investigator of the study, director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and developmental co-chair of US Oncology Lung Committee, said. "These results support the ongoing drive toward using personalized health care to dictate therapy in an attempt to optimize outcomes. A follow-up study to advance the combination toward registration is planned."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... , ... June 27, 2017 , ... ... assistance and personal financial planning services to residents of southern New Hampshire, is ... event that promises to fight hunger and homelessness in the region. , New ...
(Date:6/27/2017)... Ore. (PRWEB) , ... June 27, 2017 , ... ... (CSP), today announced the expansion of Atmosera Managed Azure Services . The ... includes enhancements in support of the company’s growing customer base. Atmosera’s next generation ...
(Date:6/27/2017)... CT (PRWEB) , ... June 27, 2017 , ... Dr. ... the recent renovation of his practice, Advanced Periodontics and Dental Implant Center of Connecticut. ... increased the administrative and waiting areas. The renovations are intended to improve patient comfort ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is ... PTSD. Yet less than 20% will receive adequate care due to lack of effective ... receive any care at all. And left untreated, veterans are at an increased risk ...
(Date:6/27/2017)... ... 2017 , ... East Los Angeles dentist, Ramin Assili DDS , comments ... happens to a woman during pregnancy can have profound effects on a developing fetus, ... on a baby’s long-term health. This study, which was performed at the University of ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon Pumps ... ... CS100i IABP ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  0998-UC-3023-XX ... This field correction also applies to any System 98 or ...
(Date:6/14/2017)... N.C. , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away ... reality platform is described by Forbes as "entering the ... American Medical Association as teaching "empathy to medical professionals ... the startup was recently named a finalist for the ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is ... for excellence as a Podiatrist in Alabama . ... at Family First Foot Care. He brings over 20 years of ... pain management and healthcare, to his role. ... Foot Care, PC is pleased to welcome you to ...
Breaking Medicine Technology: